Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | OPA1 | O60313 | 1/20 | 0.41 |
| ▸ | EIF5B | O60841 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27989542 | 0.91 | MTNR1A (0.40) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL1395799 | 0.88 | HTR2A (0.52) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL2260099 | 0.87 | HTR2A (0.52) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL2020434 | 0.84 | MTNR1A (0.59) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL27977245 | 0.84 | HTR2A (0.51) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL2023775 | 0.84 | HTR2A (0.51) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL2261530 | 0.84 | HTR2A (0.48) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL1719811 | 0.84 | MTNR1A (0.51) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL8039755 | 0.82 | HTR2A (0.49) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL13067746 | 0.82 | HTR2A (0.49) | HTR2AHTR2CMTNR1AMTNR1BMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000005-B2 | Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same | ARQULE, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2841069-A1 | HIGHLY PURE PYRROLOQUINOLINYL-PYRROLE-2,5-DIONE AND PYRROLOQUINOLINYL-PYRROLIDINE-2,5-DIONE AND METHODS OF PREPARING SAME | ARQULE, INC. (US) | 2015-03-04 | — | — | EP | disclosed |
| CN-101801961-B | Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ARQULE INC | 2014-09-24 | — | — | CN | disclosed |
| WO-2013162714-A1 | HIGHLY PURE PYRROLOQUINOLINYL-PYRROLE-2,5-DIONE AND PYRROLOQUINOLINYL-PYRROLIDINE-2,5-DIONE AND METHODS OF PREPARING SAME | ARQULE, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130281699-A1 | Highly Pure Pyrroloquinolinyl-Pyrrole-2,5-Dione and Pyrroloquinolinyl-Pyrrolidine-2,5-Dione and Methods of Preparing Same | ARQULE, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| CN-101941970-B | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer | ARQULE INC | 2013-08-21 | — | — | CN | disclosed |
| CN-101133055-B | MELEIMIDE derivatives, pharmaceutical compositions and methods for treating cancer | ARQULE INC | 2011-05-25 | — | — | CN | disclosed |
| CN-101941970-A | The MELEIMIDE derivative, pharmaceutical composition and the method that are used for the treatment of cancer | ARQULE INC | 2011-01-12 | — | — | CN | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009026446-A9 | HDAC INHIBITORS | ARQULE, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009026446-A2 | HDAC INHIBITORS | ARQULE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| CN-101133055-A | MELEIMIDE derivatives, pharmaceutical compositions and methods for treating cancer | ARQULE INC (US) | 2008-02-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | HTR2A 2994/4885HTR2C 3322/4885MTNR1A 2791/4885 |
| US-20130281699-A1 | Highly Pure Pyrroloquinolinyl-Pyrrole-2,5-Dione and Pyrroloquinolinyl-Pyrrolidine-2,5-Dione and Methods of Preparing Same | DHPS, QDPR, IDO1 | HTR2A 421/4885HTR2C 111/4885MTNR1A 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.